Brain training and new drug combo tested to fight memory loss in stroke risk patients
NCT ID NCT07605130
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a tablet-based brain training program and/or a powerful cholesterol-lowering drug (PCSK9 inhibitor) can improve thinking and memory in 420 adults aged 55-80 with narrowed brain arteries. Participants will be split into four groups, combining or not combining the training with standard or intensive cholesterol treatment. The main goal is to see if these approaches boost cognitive scores after 24 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Recaticimab (PCSK9 inhibitor) injection, plus statins and ezetimibe
What this could lead to
If successful, this could point toward a way to slow or improve cognitive decline in people with intracranial atherosclerosis.
What could go wrong
This is a Phase 4 trial with 420 participants, so results are not yet known. The cognitive training is intensive (30 min/day, 5 days/week), and the added drug may cause side effects like injection site reactions or muscle pain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COGNITIVE IMPAIRMENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100730, China
Contact Phone: •••-•••-•••• Email: •••••@•••••